title: Oral vitamin D increases the frequencies of CD38+ human B cells and ameliorates IL-17-producing T cells.
abstract: Vitamin D deficiency (serum 25-hydroxyvitamin D < 50 nm) has been associated with the onset of immunological diseases including atopic dermatitis (AD), cutaneous or systemic lupus erythematosus and allergic asthma. In this study, we assessed whether oral vitamin D (cholecalciferol) supplementation leads to a systemic modulation of the phenotype of circulating lymphocyte populations and whether a defined serum 25-hydroxyvitamin D (25(OH)D) concentration can be related to the effects on lymphocytes. Cholecalciferol was administered in a dose-escalation setting to vitamin D-deficient individuals from 2000 up to 8000 IU daily for 12 weeks. Individuals without cholecalciferol intake served as controls. Peripheral B cells and T cells were examined by multicolour flow cytometric analysis. The mean serum 25(OH)D concentrations increased upon cholecalciferol intake up to 159 ± 28.7 nm, and remained low in the control group 30.0 ± 12.5 nm. Following cholecalciferol intake, the frequencies of circulating CD38 expressing B cells were significantly increased and IFN-γ+ , and/or IL-17+ CD4+ T helper cells were decreased. These data were identified to correlate with the serum 25(OH)D levels by applying two different analysis approaches (ROC and a nonlinear regression analysis). Our data indicate that increasing 25(OH)D serum concentrations are associated with an increased expression of CD38 on B cells and a decreased T-cell-dependent proinflammatory cytokine production. The therapeutical role of our findings in systemic immunological diseases should be explored in the future by further controlled clinical studies.
authors: Klinik für Dermatologie, Venerologie und Allergologie, Allergie-Centrum-Charité, CCM, Charité - Universitätsmedizin Berlin, Berlin, Germany.
authors: Gennadiy
authors: G
authors: Drozdenko
authors: Guido
authors: G
authors: Heine
authors: Margitta
authors: M
authors: Worm
mesh_terms: D051997:ADP-ribosyl Cyclase 1 / Q000032:analysis; D000284:Administration, Oral; D000293:Adolescent; D000328:Adult; D016175:B-Lymphocyte Subsets / Q000187:drug effects*; D002112:Calcifediol / Q000097:blood; D002762:Cholecalciferol / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use; D005260:Female; D006801:Humans; D016130:Immunophenotyping; D007371:Interferon-gamma / Q000096:biosynthesis; D020381:Interleukin-17 / Q000096:biosynthesis; D008297:Male; D008562:Membrane Glycoproteins / Q000032:analysis; D008875:Middle Aged; D012372:ROC Curve; D012621:Seasons; D058504:Th17 Cells / Q000187:drug effects* / Q000378:metabolism; D014808:Vitamin D Deficiency / Q000188:drug therapy / Q000276:immunology; D055815:Young Adult
chemical_list: D020381:Interleukin-17; D008562:Membrane Glycoproteins; D002762:Cholecalciferol; D007371:Interferon-gamma; C498154:CD38 protein, human; D051997:ADP-ribosyl Cyclase 1; D002112:Calcifediol
keywords: B cells; T cells; Vitamin D; cytokines; supplementation